Bochsler P N, Slauson D O, Neilsen N R
Department of Pathology, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853.
J Leukoc Biol. 1990 Oct;48(4):306-15. doi: 10.1002/jlb.48.4.306.
The essential role of the CD11/CD18 family of leukocyte adhesion molecules (LeuCams) in neutrophil-substrate adhesion is well documented. We have found that a monoclonal antibody designated 60.3 (MoAb 60.3) that recognizes the common beta-subunit (CD18) on human neutrophils (PMN) also recognizes a surface antigen on equine PMN. Antigen expression as assessed by immunofluorescence flow cytometry was enhanced by zymosan-activated serum (ZAS) or phorbol 12-myristate 13-acetate (PMA) stimulation. Pretreatment of equine PMN with MoAb 60.3 inhibited ZAS-stimulated aggregation, indicating that the monoclonal recognized a functional epitope on equine PMN involved in adhesion-related functions. Cells pretreated only with bacterial lipopolysaccharide (LPS; 1 microgram/ml) exhibited moderate increased binding of MoAb 60.3 as determined by fluorescence intensity. Preincubation of PMN with LPS resulted in a slight increase in MoAb 60.3 binding after subsequent ZAS stimulation, greater than that with either LPS or ZAS as sole stimulus. Similarly, enhanced binding of MoAb 60.3 was observed with LPS preincubation when PMA was used as a stimulus, but this effect was dose dependent and was observed at only one of three PMA concentrations tested (1 ng/ml). In other experiments, preincubation of PMN with antiinflammatory drugs inhibited 41.5-45.1% of ZAS-stimulated PMN adhesion to monolayers of equine endothelial cells. To determine whether modulation of expression of the adhesion-related antigen recognized by MoAb 60.3 correlated with these observed adhesive responses of PMN, we used immunofluorescence flow cytometry to assess expression of the antigen on drug-treated PMN. Using 10% ZAS as a stimulus, phenylbutazone (PBZ; 100 micrograms/ml) pretreatment of PMN reduced subsequent MoAb 60.3 binding by only 12.3%, and dexamethasone (DEX; 10(-5) M) reduced binding by only 1.0%; reductions of 16.4% with PBZ and 9.3% with DEX occurred when PMA (10 ng/ml) was used as the PMN stimulant. These data suggest that equine PMN express a functional adhesion molecule similar to those found on human PMN and that LPS may enhance the expression of this surface antigen. Expression of this adhesion-related surface antigen on equine PMN does not correlate well with levels of drug-induced diminished adhesion of PMN to endothelium in vitro.
白细胞黏附分子(LeuCams)的CD11/CD18家族在中性粒细胞与底物的黏附中的重要作用已有充分记载。我们发现,一种名为60.3的单克隆抗体(MoAb 60.3)可识别人类中性粒细胞(PMN)上的共同β亚基(CD18),它也能识别马PMN上的一种表面抗原。通过免疫荧光流式细胞术评估的抗原表达,在酵母聚糖激活血清(ZAS)或佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA)刺激下会增强。用MoAb 60.3预处理马PMN可抑制ZAS刺激的聚集,这表明该单克隆抗体识别马PMN上一个参与黏附相关功能的功能性表位。仅用细菌脂多糖(LPS;1微克/毫升)预处理的细胞,通过荧光强度测定显示MoAb 60.3的结合有适度增加。PMN与LPS预孵育后,在随后的ZAS刺激下,MoAb 60.3的结合略有增加,大于单独使用LPS或ZAS作为刺激时的增加量。同样,当使用PMA作为刺激物时,LPS预孵育也观察到MoAb 60.3的结合增强,但这种效应是剂量依赖性的,且仅在测试的三个PMA浓度之一(1纳克/毫升)时观察到。在其他实验中,用抗炎药预处理PMN可抑制41.5% - 45.1%的ZAS刺激的PMN与马内皮细胞单层的黏附。为了确定MoAb 60.3识别的黏附相关抗原的表达调节是否与PMN这些观察到的黏附反应相关,我们使用免疫荧光流式细胞术评估药物处理的PMN上该抗原的表达。以10% ZAS作为刺激物时,PMN用苯基丁氮酮(PBZ;100微克/毫升)预处理后,随后MoAb 60.3的结合仅减少12.3%,地塞米松(DEX;10⁻⁵ M)预处理后结合仅减少1.0%;当使用PMA(10纳克/毫升)作为PMN刺激物时,PBZ预处理使结合减少16.4%,DEX预处理使结合减少9.3%。这些数据表明,马PMN表达一种与人类PMN上发现的类似的功能性黏附分子,且LPS可能增强这种表面抗原的表达。马PMN上这种黏附相关表面抗原的表达与体外药物诱导的PMN与内皮细胞黏附减少的水平相关性不佳。